GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX - Get Free Report) has received an average recommendation of "Moderate Buy" from the eleven brokerages that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokers that have covered the stock in the last year is $7.84.

A number of analysts have recently weighed in on the company. Truist Financial cut their target price on GoodRx from $6.50 to $5.50 and set a "hold" rating for the company in a research report on Thursday, April 10th. Wells Fargo & Company reduced their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research report on Tuesday. Citigroup decreased their target price on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. Finally, KeyCorp dropped their price target on GoodRx from $7.00 to $6.00 and set an "overweight" rating for the company in a research note on Wednesday, January 8th.

GoodRx Price Performance

Shares of GDRX stock traded up $0.03 during trading on Friday, hitting $4.66. The company had a trading volume of 448,983 shares, compared to its average volume of 1,375,401. The firm has a market capitalization of $1.79 billion, a P/E ratio of -155.33, a price-to-earnings-growth ratio of 2.46 and a beta of 1.25. GoodRx has a one year low of $3.82 and a one year high of $9.26. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The stock's 50-day moving average price is $4.57 and its 200 day moving average price is $4.87.

Institutional Investors Weigh In On GoodRx

A number of institutional investors have recently made changes to their positions in GDRX. National Bank of Canada FI lifted its stake in shares of GoodRx by 34.9% in the fourth quarter. National Bank of Canada FI now owns 8,308 shares of the company's stock worth $39,000 after acquiring an additional 2,151 shares during the period. RPO LLC acquired a new position in shares of GoodRx in the 4th quarter worth approximately $52,000. Versor Investments LP bought a new stake in shares of GoodRx in the 4th quarter valued at $54,000. Verus Capital Partners LLC bought a new stake in GoodRx during the fourth quarter valued at $55,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in GoodRx during the fourth quarter worth approximately $56,000. Institutional investors own 63.77% of the company's stock.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.